GLENMARK2,403.10

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹67,815 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)290.47368.31422.84422.84
Receivable Days (DSO)57.4291.57106.68106.68
Payable Days (DPO)293.12313.71461.43482.86
Cash Conversion Cycle (days)54.77146.1768.0946.66
Working Capital Turnover7.344.003.453.60
Asset Turnover0.820.830.850.85
Cash Conversion (CFO/Net Income)0.19-0.792.532.53
CFO/EBITDA-0.22-0.350.750.75
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.